{"entity":{"id":"nct06534060","kind":"trial","name":"MB-105 in Patients With CD5 Positive T-cell Lymphoma","aka":[],"tldr":"A phase 2 trial of Genetic: MB-105 in non-Hodgkin lymphoma, run by March Biosciences Inc, now recruiting.","summary":"MB-105 in Patients With CD5 Positive T-cell Lymphoma is a phase 2 interventional study registered as NCT06534060 by March Biosciences Inc, with 46 participants planned, started 2025-02-15 and due to reach its primary completion in 2028-02. Interventions recorded: Genetic: MB-105.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06534060","url":"https://clinicaltrials.gov/study/NCT06534060"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["non-hodgkin-lymphoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06534060","phase":"2","setting":"A Phase 2, Open-label, Multicenter Study of MB-105 in Patients With CD5 Positive (CD5+) Relapsed / Refractory T-cell Lymphoma (r/r TCL).","sponsor":"March Biosciences Inc","enrolled":46,"outcomes":[]},"route":"/trials/nct06534060/","neighbours":{"cancer":[{"id":"non-hodgkin-lymphoma","kind":"cancer","name":"Non-Hodgkin lymphoma (all types)","route":"/cancers/non-hodgkin-lymphoma/"}]}}